Are Procyanidin-Based Hair Tonics or Shampoos Effective Against Androgenic Alopecia?

Androgenic alopecia (AGA) — also known as male or female pattern hair loss — is a chronic, progressive condition driven by a genetic sensitivity of hair follicles to dihydrotestosterone (DHT), a metabolite of testosterone. **This hormone binds to androgen receptors in scalp follicles, shortening the anagen phase (growth phase) and gradually miniaturizing terminal hairs into thin vellus hairs. **

**The process is irreversible without intervention and affects both men and women, though with different patterns and rates. **

Conventional treatments approved by the U.S. Food and Drug Administration (FDA) include topical minoxidil and oral finasteride, which target vasodilation and hormonal pathways respectively. However, due to side effects, costs, and variable responses, attention has shifted toward natural or plant-derived alternatives such as procyanidins.

What Are Procyanidins and Why Are They Considered Promising?

Procyanidins are polyphenolic compounds naturally found in foods like apples, grapes, and cocoa. They are classified as oligomeric flavan-3-ols, meaning they are small chains of catechins and epicatechins. **Laboratory studies attribute their activity to antioxidant and anti-inflammatory properties and to effects on cell proliferation and signalling pathways involved in hair growth; these effects have not been shown in the human scalp. **

In follicular biology, it has been hypothesized that procyanidins promote hair regeneration by stimulating the proliferation of hair epithelial cells, prolonging the anagen phase, and possibly inhibiting transforming growth factor-beta (TGF-β), a molecule known to induce catagen (the regression phase of the hair cycle).

Evidence from Research: What Has Been Observed So Far?

Preclinical studies have suggested that topical procyanidins can activate hair follicle cells and promote regrowth. In 1999, Takahashi et al. reported a study on shaved C3H mice in which topical procyanidin B-2 was followed by regrowth over about 70% of the shaved area, compared with about 42% with the vehicle alone. Two other procyanidins, B-3 and C-1, did as well or better in the same test. However, such animal data, while encouraging, cannot be directly extrapolated to human scalp physiology without clinical confirmation.

Clinical Trials in Humans

The first human randomized double-blind clinical trial evaluating 1% topical procyanidin B-2 was conducted by Takahashi et al. (2001) at the Tsukuba Research Laboratories of Kyowa Hakko Kogyo, the company that developed the ingredient. The study included 29 men with male pattern hair loss. Nineteen received procyanidin B-2 lotion, and ten received placebo, applied twice daily for four months. **Hair density was evaluated by phototrichogram and photomicrograph analysis in a 0.25 cm² target area. **

Results indicated a statistically significant increase in total hair count (+3.67 hairs/0.25 cm² versus -2.54 in placebo, p < 0.001) and in the share of men whose mean hair diameter increased (78.9% vs 30.0%, p < 0.02). No adverse effects were reported. The authors described procyanidin B-2 as a potential hair-growing agent (Takahashi et al., 2001).

A later trial by Takahashi et al. (2005) included 43 men using a 0.7% apple procyanidin oligomer lotion. After a 6-month placebo-controlled phase, hair counts had changed by +3.3 per 0.5 cm² in the procyanidin group and -3.6 in the placebo group; the procyanidin group then continued treatment to 12 months in total. Individual responses varied widely. Long-term results and what happens after stopping remain unknown.

All three procyanidin-only trials were run by Kyowa Hakko Kogyo, which developed the ingredient. No independent group has repeated them.

A more recent randomized, double-blind, placebo-controlled trial by Yeniay and Arca (2022) examined 40 male patients with androgenic alopecia (Hamilton-Norwood II-V). Participants used a topical spray containing 1% procyanidin B-2 with biotin and dexpanthenol or a placebo vehicle twice daily for 16 weeks. Hair counts and anagen/telogen ratios were evaluated using TrichoScan digital analysis.

The treatment group showed significant increases in total hair count and anagen ratio (from 1.60 ± 0.16 to 1.69 ± 0.18, p < 0.005), while placebo results remained unchanged. Mild scalp redness occurred in a few participants, but no serious adverse effects were recorded. Although promising, this study’s short duration and the presence of multiple active ingredients complicate attribution of results solely to procyanidin B-2.

Critical Analysis: Where Does the Evidence Stand?

The published trials reported modest changes in hair counts and thickness, with few side effects reported. However, from a critical perspective, the evidence base remains limited in both scale and duration. The sample sizes in published human trials are small, ranging from 29 to 43 participants, and treatment durations typically span four to six months — insufficient to assess sustained regrowth or long-term safety.

Moreover, the mechanism of action, while biologically plausible, is not fully elucidated. The hypothesis that procyanidins stimulate anagen re-entry or inhibit catagen-inducing factors like TGF-β has not been directly demonstrated in vivo in human follicles. Additionally, formulations often include other compounds (e.g., biotin, dexpanthenol), making it difficult to isolate the independent effect of procyanidin.

When compared to established treatments such as minoxidil, which has robust, multi-year clinical data and FDA approval, procyanidin-based therapies remain experimental. No comparative trials have yet shown parity or superiority over minoxidil or finasteride, and no regulatory authority currently lists procyanidin as an approved active ingredient for androgenic alopecia. Short trials reported few side effects, but there is no long-term safety data.

Conclusion: An Emerging but Unproven Alternative

Small, company-run trials reported a modest effect of topical procyanidin on hair counts in men with androgenic alopecia. The proposed mechanism, from laboratory and mouse work, involves cell-proliferation and antioxidant pathways; it has not been shown in human follicles. Nevertheless, clinical trials remain limited in size and duration, and no large-scale, long-term randomized studies have yet validated its sustained efficacy.

For now, procyanidin-based shampoos and tonics should be viewed as experimental or adjunctive rather than primary therapies. Whether they work will only be known from larger, independently funded clinical trials.

References (APA 7th Edition)

Takahashi, T., Kamimura, A., Kagoura, M., Toyoda, M., & Morohashi, M. (2005). Investigation of the topical application of procyanidin oligomers from apples to identify their potential use as a hair-growing agent. Journal of Cosmetic Dermatology, 4(4), 245–249. Retrieved from https://pubmed.ncbi.nlm.nih.gov/17168871/

Takahashi, T., Kamiya, T., Hasegawa, A., & Yokoo, Y. (1999). Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells in vitro and activate hair follicle growth in vivo. Journal of Investigative Dermatology, 112(3), 310–316. Retrieved from https://pubmed.ncbi.nlm.nih.gov/10084307/

Takahashi, T., Kamimura, A., Yokoo, Y., Honda, S., & Watanabe, Y. (2001). The first clinical trial of topical application of procyanidin B-2 to investigate its potential as a hair-growing agent. Phytotherapy Research, 15(4), 331–336. Retrieved from https://pubmed.ncbi.nlm.nih.gov/11406858/

Yeniay, Y., & Arca, E. (2022). Evaluation of the efficacy and safety of topical procyanidin B2 and placebo in the treatment of androgenetic alopecia in men: A randomized, double-blind, placebo-controlled study. Turkish Journal of Dermatology, 16(4), 108–114. Retrieved from https://journals.lww.com/tjod/fulltext/2022/16040/evaluation_of_the_efficacy_and_safety_of_topical.2.aspx

Gupta, A. K., Wang, H., Wang, T., & Talukder, M. (2025). Do non-prescription products help in managing androgenic alopecia? Skin Appendage Disorders, 11(3), 270–281. PMID 40475103. Retrieved from https://karger.com/sad/article/11/3/270/917486

Gupta, A. K., Talukder, M., Keene, S., Williams, G., & Bamimore, M. A. (2025). Comparative effect of conventional and non-conventional over-the-counter treatments for male androgenetic alopecia: A systematic review and network meta-analysis. International Journal of Molecular Sciences, 26(16), 7920. PMID 40869239. Retrieved from https://www.mdpi.com/1422-0067/26/16/7920